Kallol Basu

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 337 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Duane E. DeMong, Thomas J. Greshock et al. · Journal of Medicinal Chemistry · 2017 · 148 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Evolution of the Total Synthesis of (−)-Okilactomycin Exploiting a Tandem Oxy-Cope Rearrangement/Oxidation, a Petasis−Ferrier Union/Rearrangement, and Ring-Closing Metathesis

Amos B. Smith, Todd Bosanac, Kallol Basu · Journal of the American Chemical Society · 2009 · 72 citations · Full text

Pharmacy, Medicinal Chemistry, Bioorganic Chemistry +16

Total Synthesis of (−)-Okilactomycin

Amos B. Smith, Kallol Basu, Todd Bosanac · Journal of the American Chemical Society · 2007 · 69 citations

Natural Sciences, Chemistry, Medicinal Chemistry +13

The Leader's Role in Managing Change: Five Cases of Technology‐Enabled Business Transformation

Kallol Basu · Global Business and Organizational Excellence · 2015 · 48 citations

Management, Change Management, Leadership +17